Bavarian Cancer Research Center (BZKF), Augsburg, Germany.
Department of Otolaryngology - Head and Neck Surgery, Augsburg University Hospital, Augsburg, Germany.
Head Neck. 2024 Nov;46(11):2890-2900. doi: 10.1002/hed.27910. Epub 2024 Aug 20.
Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan-Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (n = 9) was 44.4%. The IPD analysis (n = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.
诱导化疗（IC）最近在治疗鼻腔鼻窦未分化癌（SNUC）方面的作用变得越来越重要。我们分析了我们的 SNUC 病例，并进行了荟萃分析，重点关注按治疗分层的生存率。对我院的 SNUC 病例进行了回顾性评估。进行了系统的文献复习，以分析 SNUC 的治疗和结果。为了计算 5 年和 2 年总生存率（OS），使用 Kaplan-Meier 估计器和 Cox 比例风险回归分析对个体患者数据（IPD）进行分析，以确定治疗类型与生存之间的关系。对于没有 IPD 数据的研究，应用随机效应模型进行 5 年生存率的汇总估计。我们的 SNUC 病例（n=9）的 5 年 OS 为 44.4%。IPD 分析（n=192）显示，接受诱导化疗的患者的 5 年 OS 显著提高（72.6% vs. 44.5%）。文献检索中确定的 13 项研究的汇总 5 年 OS 为 43.8%。对于诊断为 SNUC 的每个患者，都应考虑使用 IC。
